A Pilot Study of TGF-beta as a Potential Target for Prevention of Radiation-Induced Injury
- To determine whether there is a dose-dependent increase in TGF-beta following
radiotherapy in patients with epithelial cancers.
OUTLINE: Patients undergo blood sample collection prior to treatment, 24-72 hours after the
first fraction of radiotherapy, and at the end of radiotherapy. Patients will also be asked
for a weekly blood sample, but this is optional. Samples are analyzed to compare pre- and
post-treatment TGF-beta levels.
Observational Model: Cohort, Time Perspective: Prospective
TGF-beta is a protein that can be detected in the blood.
day 1 prior to treatment, 24-72 hours after 1st treatment, weekly at treatment (optional) and at completion of treatment
A. Bapsi Chakravarthy, MD
Vanderbilt-Ingram Cancer Center
United States: Vanderbilt University Human Research Protection Program
VICC RAD 0576
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|
|Vanderbilt-Ingram Cancer Center - Cool Springs||Nashville, Tennessee 37064|
|Vanderbilt-Ingram Cancer Center at Franklin||Nashville, Tennessee 37064|